Hutchmed (China) announced that its partner Takeda Pharmaceutical Company has received approval from the European Commission for FRUZAQLA® (fugui teni) to treat refractory metastatic colorectal cancer patients. This is based on the positive results of the global Phase III clinical trial FRESCO-2, marking the first approved innovative targeted therapy in the European Union in over a decade. FRUZAQLA® is a selective inhibitor of all three VEGFR subtypes, providing new treatment options for metastatic colorectal cancer patients and clinical physicians. Dr. Su Weiguo, CEO and Chief Scientific Officer of Hutchmed, stated that this is the company's first approved product in Europe, and this goal was achieved in a short period of time through cooperation with Takeda. FRUZAQLA® has been confirmed...Show More

Hutchmed (China) announced that its partner Takeda Pharmaceutical Company has received approval from the European Commission for FRUZAQLA® (fugui teni) to treat refractory metastatic colorectal cancer patients. This is based on the positive results of the global Phase III clinical trial FRESCO-2, marking the first approved innovative targeted therapy in the European Union in over a decade. FRUZAQLA® is a selective inhibitor of all three VEGFR subtypes, providing new treatment options for metastatic colorectal cancer patients and clinical physicians. Dr. Su Weiguo, CEO and Chief Scientific Officer of Hutchmed, stated that this is the company's first approved product in Europe, and this goal was achieved in a short period of time through cooperation with Takeda. FRUZAQLA® has been confirmed and accepted for market approval application by the European Medicines Agency in June 2023, and FRESCO-2 study data published in The Lancet in June of the same year supported the application. Colorectal cancer is the third most common cancer globally and the second most common cancer in Europe, with limited treatment options. The approval of FRUZAQLA® brings new hope to patients.